Cancer statistics, 1996

Parker, Sheryl L.; Tong, Tony; Bolden, Sherry; Wingo, Phyllis A.

doi:10.3322/canjclin.46.1.5

Cited by 1,754 publications

(768 citation statements)

References 3 publications

Supporting

Mentioning

717

Contrasting

Unclassified

Order By: Relevance

“…The outlook for patients with ductal adenocarcinoma of the head of the pancreas remains poor, having the lowest 5-year survival rate of any cancer (Parker et al, 1996). Surgery remains the only proven approach for improving survival in these patients.…”

mentioning

confidence: 99%

Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas

et al. 2004

View full text Add to dashboard Cite

The aim of the present study was to examine the relationship between the clinicopathological status, the pre-and postoperative systemic inflammatory response and survival in patients undergoing potentially curative resection for ductal adenocarcinoma of the head of the pancreas. Patients (n ¼ 65) who underwent resection of ductal adenocarcinoma of the head of pancreas between 1993 and 2001, and had pre-and postoperative measurements of C-reactive protein, were included in the study. The majority of patients had stage III disease (International Union Against Cancer Criteria, IUCC), positive circumferential margin involvement (R 1 ), tumour size greater than 25 mm with perineural and lymph node invasion and died within the follow-up period. On multivariate analysis, tumour size (hazard ratio (HR) 2.10, 95% confidence interval (CI) 1.20 -3.68, P ¼ 0.009), vascular invasion (HR 2.58, 95% CI 1.48 -4.50, Po0.001) and postoperative C-reactive protein (HR 2.00, 95% CI 1.14 -3.52, P ¼ 0.015) retained independent significance. Those patients with a postoperative C-reactive protein p10 mg l À1 had a median survival of 21.5 months compared with 8.4 months in those patients with a C-reactive protein 410 mg l À1 (Po0.001). The results of the present study indicate that, in patients who have undergone potentially curative resection for ductal adenocarcinoma of the head of pancreas, the presence of a systemic inflammatory response predicts poor outcome.

show abstract

mentioning

confidence: 99%

Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Lung cancer was the most common cause of cancer death in 1996 in the United States and Germany (Parker, 1996). The World Health Organization histologic classification of lung cancer (World Health Organization, 1982) describes 3 major subtypes of non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC), adenocarcinoma (AC) and large cell carcinoma (LC) which represent approximately 75% of all lung cancer cases.…”

mentioning

confidence: 99%

Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer

et al. 2000

View full text Add to dashboard Cite

Summary A prospective study was performed in patients with non-small cell lung cancer (NSCLC) to evaluate the prognostic importance of multiple molecular marker (p53, c-Ki-ras, c-erbB-2) testing. 103 patients with potentially curative resections (RO resection) for NSCLC in histopathological stages I-IIIA were included. SSCP analysis and DNA sequencing for p53 and c-Ki-ras genes were performed on paired tumour and normal lung tissue samples and immunohistochemistry (c-erbB-2) was done on frozen tissue sections with a specific anti-c-erbB-2 monoclonal antibody. 46/103 (44.6%) NSCLC showed p53 mutations and 17/103 (16.5%) c-Ki-ras mutations including 12/37 (32.4%) adenocarcinomas. Overexpression of c-erbB-2 (p185) was detected in 56/103 (54.4%) tumours. 24/103 (23.3%) NSCLC were negative for alterations in all 3 parameters (c-Ki-ras, p53 and p185) whereas 79/103 (76.7%) were positive for at least one of the 3 parameters. In a regression model including a multiple molecular marker parameter (negative for all 3 markers versus positive for at least one marker), histopathological stage (P < 0.00001), respectively the pT (P < 0.01) and pN (P < 0.00001) categories and the multiple molecular marker parameter (P < 0.01) were of significant prognostic importance. This study demonstrates that testing 3 molecular markers (c-Ki-ras, p53 and c-erbB-2) improves estimation of prognosis compared to single marker testing and appears to define low (82.6% ± 7.9% 5-year survival) and high risk (40.2% ± 5.5% 5-year survival) groups for treatment failure in potentially curative (RO) resected NSCLC.

show abstract

“…1 Androgen deprivation is the standard therapy for newly diagnosed metastatic cancer and produces symptomatic improvements in 60-70% of patients, but results in only a small prolongation in both progressionfree survival and overall survival. 2 In fact, despite initially effective hormonal ablation therapy for patients with metastatic prostate carcinoma, the majority of these patients progress to a hormone refractory state, with a median survival of less than 2 years.…”

Section: Introductionmentioning

confidence: 99%

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Bernardi

Talamini

Zanetti

et al. 2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone-prednisone.

show abstract

Cancer statistics, 1996

Cited by 1,754 publications

References 3 publications

Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas

Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas

Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Contact Info

Product

Resources

About